To fully evaluate the genetics of renal glucosuria and its pharmacogenetic effect on SGLT2 inhibitors, future studies should subject heterozygotes and homozygotes over a wide spectrum of variants in a diverse population to different SLGT2 inhibitors and with varying glucose concentrations. The gene discussed is SLC5A2; the disease is Renal glucosuria.